Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today Here's What Happened
Maze Therapeutics, Inc. (MAZE) on Thursday announced that it has entered into a securities purchase agreement for the private placement of its securities for gross proceeds of about $150 million. Shares of the company soared 24% in the pre-market session at the time of writing.
The private placement involves the sale of over four million shares of common stock at $16.25 apiece, implying a premium of over 1% from the stock's closing price on Wednesday. The placement is expected to close on September 12, the company said, while adding that both new and existing investors will participate.
The firm said that the private placement includes participation from Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare-dedicated funds.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Japan Buy Now Pay Later Market Size To Surpass USD 145.5 Billion By 2033 CAGR Of 22.23%
- BTCC Summer Festival 2025 Unites Japan's Web3 Community
- GCL Subsidiary, 2Game Digital, Partners With Kucoin Pay To Accept Secure Crypto Payments In Real Time
- Smart Indoor Gardens Market Growth: Size, Trends, And Forecast 20252033
- Nutritional Bar Market Size To Expand At A CAGR Of 3.5% During 2025-2033
- Pluscapital Advisor Empowers Traders To Master Global Markets Around The Clock
Comments
No comment